As of Sep 18
| -0.03 / -2.50%|
The 2 analysts offering 12-month price forecasts for VistaGen Therapeutics Inc have a median target of 2.35, with a high estimate of 4.00 and a low estimate of 0.70. The median estimate represents a +100.85% increase from the last price of 1.17.
The current consensus among 3 polled investment analysts is to Buy stock in VistaGen Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.